Technical Analysis for VTVT - vTv Therapeutics Inc.

Grade Last Price % Change Price Change
grade B 2.82 1.81% 0.05
VTVT closed up 1.47 percent on Wednesday, February 19, 2020, on 72 percent of normal volume.
Earnings due: Feb 20
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical VTVT trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 1.81%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.81%
Doji - Bullish? Reversal 1.81%
Earnings Movers Other 1.81%
Outside Day Range Expansion 1.81%
Wide Bands Range Expansion 1.81%
1,2,3 Pullback Bullish Bullish Swing Setup 3.30%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.30%
Calm After Storm Range Contraction 3.30%
Wide Bands Range Expansion 3.30%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

vTv Therapeutics Inc., a biopharmaceutical company, engages in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease includes azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. The company's type 2 diabetes drug candidates comprise TTP399, an orally administered, liver-selective glucokinase activator, which is in a Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor that has completed Phase I clinical trials. It is also developing HPP593, a functionally selective peroxisome proliferator-activated receptor delta agonist for the prevention of muscle weakness associated with prolonged mechanical ventilation and critical injury that has completed Phase Ib clinical trials; HPP737, an orally administered phosphodiesterase-4 inhibitor for the treatment of chronic obstructive pulmonary disease, psoriasis, and other inflammatory diseases, which has completed Phase Ib clinical trials; and HPP971, a Bach1 inhibitor, for the treatment of inflammation, autoimmune diseases, and diseases associated with oxidative stress, which is in Phase 1 clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to research, develop, and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina.
Medicine Chemistry Biopharmaceutical Diseases Diabetes Autoimmune Diseases Inflammation Alzheimer's Disease Psoriasis Parkinson's Disease Organic Chemistry Inflammatory Diseases Chronic Obstructive Pulmonary Disease Pyridines Treatment Of Alzheimer's Disease Tyrosine Kinase Inhibitors Biotie Therapies Mechanical Ventilation Treatment Of Chronic Obstructive Pulmonary Disease Buparlisib Treatment Of Inflammation

Is VTVT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.23
52 Week Low 1.23
Average Volume 894,231
200-Day Moving Average 1.61
50-Day Moving Average 2.07
20-Day Moving Average 2.48
10-Day Moving Average 2.69
Average True Range 0.32
ADX 41.26
+DI 40.67
-DI 19.81
Chandelier Exit (Long, 3 ATRs ) 3.26
Chandelier Exit (Short, 3 ATRs ) 2.87
Upper Bollinger Band 3.28
Lower Bollinger Band 1.69
Percent B (%b) 0.68
BandWidth 63.79
MACD Line 0.23
MACD Signal Line 0.20
MACD Histogram 0.0278
Fundamentals Value
Market Cap 26.85 Million
Num Shares 9.69 Million
EPS -1.67
Price-to-Earnings (P/E) Ratio -1.66
Price-to-Sales 535.97
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.40
Resistance 3 (R3) 3.39 3.16 3.30
Resistance 2 (R2) 3.16 3.00 3.17 3.26
Resistance 1 (R1) 2.97 2.90 3.07 2.98 3.22
Pivot Point 2.74 2.74 2.79 2.75 2.74
Support 1 (S1) 2.55 2.58 2.65 2.56 2.32
Support 2 (S2) 2.32 2.48 2.33 2.28
Support 3 (S3) 2.13 2.32 2.25
Support 4 (S4) 2.14